A paradigm shift within the therapy of persistent lymphocytic leukemia (CLL) has taken place over the previous decade, as therapies have progressed from offering palliative aid to inducing full remission, eradicating minimal illness and bettering survival. The event of Rituxan® (rituximab) and its use in immunochemotherapy regimens has remodeled the therapy of CLL and...
Medicine patent pool–pharma philanthropy or PR?
Merck lately signed an settlement with The Medicines Patent Pool (MPP) to license mental property regarding pediatric formulations of its integrase HIV drug, raltegravir (Ral) (the ‘Settlement’). The Settlement is alleged to clear the best way for cheaper formulations to be used in growing and a few center revenue international locations and permits for...